Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.70 |
| ▸ | PDE6D | O43924 | 1/20 | 0.60 |
| ▸ | PDE6A | P16499 | 1/20 | 0.60 |
| ▸ | PDE6G | P18545 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.60 |
| ▸ | PDE6B | P35913 | 1/20 | 0.60 |
| ▸ | PDE6C | P51160 | 1/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.60 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8361742 | 0.92 | PDE5A (0.68) | PDE5APDE6DPDE6APDE6GPDE4A | |
| SCHEMBL6674583 | 0.92 | PDE5A (0.70) | PDE5APDE6DPDE6APDE6GPDE4A | |
| SCHEMBL6674585 | 0.92 | PDE5A (0.70) | PDE5APDE6DPDE6APDE6GPDE4A | |
| SCHEMBL16312837 | 0.92 | PDE5A (0.60) | PDE5APDE6DPDE6APDE6GPDE4A | |
| SCHEMBL13409588 | 0.90 | PDE5A (0.75) | PDE5APDE6DPDE6APDE6GPDE4A | |
| SCHEMBL16312832 | 0.90 | PDE5A (0.69) | PDE5APDE6DPDE6APDE6GPDE4A | |
| SCHEMBL6628079 | 0.90 | PDE5A (0.77) | PDE5APDE6DPDE6APDE6GPDE4A | |
| SCHEMBL6628075 | 0.90 | PDE5A (0.77) | PDE5APDE6DPDE6APDE6GPDE4A | |
| SCHEMBL10201517 | 0.88 | PDE5A (0.67) | PDE5APDE6DPDE6APDE6GPDE4A | |
| SCHEMBL6626597 | 0.85 | PDE5A (0.56) | PDE5APDE6DPDE6APDE6GPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10238660-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10010553-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010553-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20160375028-A1 | ORGANIC COMPOUNDS | FIENBERG ALLEN A (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468637-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9468637-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9198924-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9198924-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | disclosed |
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | disclosed |
| US-20100087450-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087450-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| EP-1790652-A1 | Polycyclic guanine phosphodiesterase V inhibitors | Schering Corporation (US) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053190-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | PDE5A 1/4885PDE6D 117/4885PDE6A 14/4885 |
| US-10010553-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | PDE5A 1/4885PDE6D 117/4885PDE6A 14/4885 |
| US-20160375028-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | PDE5A 1/4885PDE6D 117/4885PDE6A 14/4885 |
| US-20100087450-A1 | ORGANIC COMPOUNDS | PDE3A, PDE5A, PDE2A | PDE5A 2/4885PDE6D 76/4885PDE6A 42/4885 |
| US-10238660-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | PDE5A 1/4885PDE6D 117/4885PDE6A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.